Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.

ABSTRACT:

Background

Screening for colorectal cancer (CRC) is effective at reducing mortality, but nearly 35% of eligible patients do not get screened. New noninvasive screening methods may help increase CRC screening participation. Current CRC screening methods include blood-based screening with methylated Septin 9 (SEPT9) DNA (Epi proColon), stool-based screening with fecal immunochemical testing (FIT), and the multianalyte fecal test combining FIT and stool DNA (Cologuard).

Objectives

To estimate the cost and clinical implications to health plans, including the clinical and fiscal implications of the use of blood-based screening with SEPT9 DNA, FIT, and FIT/stool DNA, for patients who are unwilling or unable to undergo other recommended screening methods, and to quant

SUBMITTER: Roth JA 

PROVIDER: S-EPMC6979046 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature